For how we live.
The professional guideline now frames recovery as an ongoing process through at least 12 weeks, and one pelvic-floor study found birth injuries still resolving a full year after delivery.
Hospital admissions for food anaphylaxis in the UK rose 5.7% a year for two decades while the case fatality rate fell. The treatment recommendations have almost no randomised evidence behind them.
An umbrella review of the meta-analyses puts the association at RR 1.45. The AUA's guideline treats ED as a risk marker, and classes shockwave, stem cell and PRP therapy as investigational.
A Cochrane review of 50 trials found cranberry products lower UTI risk in women with recurrent infections and in children, but no benefit in the elderly, in pregnancy, or in bladder-emptying problems.
A joint AGA and ACG guideline graded ten treatments for chronic constipation. The cheap osmotic laxative and the newest secretagogues sit in the same recommendation tier.
A Cochrane review found sit-stand desks reliably reduce workplace sitting, but graded the evidence low quality and could not tie it to better health. WHO backs cutting sedentary time but set no number.
Hormones, surgery and painkillers can reduce pain and improve fertility, but none reliably alter the disease itself — and even removing the uterus does not guarantee the disease goes with it.
Adding an inhaled steroid to the as-needed inhaler roughly halved severe attacks against a short-acting reliever, at a fraction of the daily steroid exposure that maintenance therapy delivers.
The 2023 global guideline puts lifestyle first for everyone, letrozole first for fertility, and the pill for cycles and excess hair — while rating much of its own evidence low to moderate quality.
US guidance recommends mammography from 40. A Canadian review of the same randomised evidence put the benefit at 0.27 fewer breast cancer deaths per 1,000 women aged 40-49 over ten years.
A Cochrane review of 11 trials found flight stockings sharply cut silent deep-vein clots. But across nearly 2,900 passengers, the trials recorded no pulmonary embolism, death, or symptomatic clot at all.
In a trial of 1,643 men, prostate cancer killed 3.1% of the monitored group and 2.2% of the surgery group — a difference the trial could not distinguish from chance. Metastases were twice as common.
That is the 23-year result from the largest randomised trial. A 2026 Cochrane review of 789,086 men rates the mortality benefit moderate-certainty and the harms largely unmeasured.
Two Cochrane reviews back scopolamine and first-generation antihistamines for preventing motion sickness. Both found the same gap: not a single randomised trial has looked at relieving symptoms already under way.
Bloating and visible distension are different problems with different mechanisms. The 2025 ESNM/UEG consensus found visceral hypersensitivity, not gas volume, doing most of the work.
Two American guideline bodies grade cognitive behavioural therapy for insomnia as a strong recommendation. Every drug in the sleep-medicine guideline — the ones it endorses and the ones it rejects — came out weak.
Expert guidelines back antibiotics for moderate-to-severe cases and simple measures for mild ones. The popular Pepto-Bismol prevention habit rests on 1980s data — and a 2025 trial could not confirm it worked.
A dose-response meta-analysis of 94 cohorts and more than 30 million people found the steepest part of the curve sits between zero and the recommended weekly dose, with small and uncertain gains above double it.
A 160-study meta-analysis found real but moderate symptom reductions while patients are on treatment. The evidence for lasting benefit after stopping is much thinner, and rests mainly on grass.
A Cochrane review of 64 trials found acetazolamide cut the risk of acute mountain sickness by about half. It is a genuine drug effect, not a folk remedy — and it is a prescription decision, not a supplement.
A network meta-analysis found six treatments clearing the clinically important threshold in the short term. It also graded 98.6% of the evidence very low certainty, and found nothing that held up past a year.
The numbers most methods advertise are perfect-use figures from clinical trials. In everyday use the pill fails about seven users in 100 a year, the condom about 13, withdrawal about 20.
The number most people quote is not the number the American Academy of Sleep Medicine and Sleep Research Society agreed on. Their recommendation is a floor, set by expert vote rather than by trial.
A Cochrane review found melatonin reduced jet lag in nine of ten trials. Sleep medicine's own guideline rates it a first-tier option for jet lag disorder. Take it at the wrong hour and it can make things worse.
Six randomised trials found no benefit from immediate imaging over usual care. A separate review explains the reason: most of what a scan finds is present in people with no pain at all.
The American College of Gastroenterology suggests a positive diagnostic strategy over a diagnosis of exclusion, with two blood and stool tests doing most of the ruling-out that is actually warranted.
The ADA's 2026 Standards of Care add guidance on individualising obesity-drug dosing, name two eating patterns for type 2 diabetes prevention, and recommend continuous glucose monitoring from diagnosis.
The recommendations are conditional, cover three drugs, and come with a projection that fewer than one in ten people who could benefit will have access by 2030.
The 27 recommendations cover monitoring, diet and medication for type 1, type 2 and gestational diabetes. WHO had guidance on diabetes and guidance on pregnancy, but never on the two together.
The recommendation covers people weighing at least 35 kg and rests on two trials in which lenacapavir cut HIV infections by 100% and 96% against background incidence.
ALEG's position holds that testosterone in postmenopausal women should be limited to hypoactive sexual desire disorder, and that pellets and compounded formulations are not recommended.
An EMAS clinical guide sets out how to manage endometriosis after menopause, advising against oestrogen-only hormone therapy even in women who have had a hysterectomy.
The guidelines pair the new injectable with a second, quieter recommendation: use simplified rapid diagnostic testing to start and continue long-acting PrEP, rather than more complex assays.